Pharmaceutical marketing has become a mainstay in US health care delivery and
traditionally has been directed toward physicians. In an attempt to address potential undue …

Transparency has become one of the primary themes in health care reform efforts in the
United States and across the world. In the face of exorbitant drug prices, high levels of …

Hospital and healthcare administrators name high prescription drug costs as one of their
largest problems. A significant body of research demonstrates that meals and honoraria from …

Objective. To assess legislation requiring drug companies to report gifts to providers, and to
evaluate the information obtained. Data Sources. Data included legislation in Vermont …

With the passage of the Physician Payment Sunshine Act as part of the federal health care
reform law, pharmaceutical manufacturers are now required to disclose a wide range of …

ContextRecent legislation in 5 states and the District of Columbia mandated state disclosure
of payments made to physicians by pharmaceutical companies. In 2 of these states, Vermont …

Public disclosure of industry payments to physicians is one way to address financial conflicts
of interest in medicine. As part of the Patient Protection and Affordable Care Act, the …

US pharmaceutical companies frequently pay doctors to promote their drugs. This has
raised concerns about conflict of interest, which policy makers have attempted to address by …

Society has clearly benefitted from the partnership between the pharmaceutical and medical
device industries. For more than 100 years there has been an unwritten understanding that …

In addition, the Physician Payment Sunshine Act, a part of the 2010 health reform law, will
soon require all pharmaceutical and medical device companies to to physicians. The first …